Premium
Effects of intranasal insulin on endogenous glucose production in insulin‐resistant men
Author(s) -
Xiao Changting,
Dash Satya,
Stahel Priska,
Lewis Gary F.
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13289
Subject(s) - endogeny , insulin , nasal administration , production (economics) , insulin resistance , medicine , endocrinology , economics , pharmacology , macroeconomics
The effects of intranasal insulin on the regulation of endogenous glucose production (EGP) in individuals with insulin resistance were assessed in a single‐blind, crossover study. Overweight or obese insulin‐resistant men ( n = 7; body mass index 35.4 ± 4.4 kg/m 2 , homeostatic model assessment of insulin resistance 5.6 ± 1.6) received intranasal spray of either 40 IU insulin lispro or placebo in 2 randomized visits. Acute systemic spillover of intranasal insulin into the circulation was matched with a 30‐minute intravenous infusion of insulin lispro in the nasal placebo arm. EGP was assessed under conditions of a pancreatic clamp with a primed, constant infusion of glucose tracer. Under these experimental conditions, compared with placebo, intranasal administration of insulin did not significantly affect plasma glucose concentrations, EGP or glucose disposal in overweight/obese, insulin‐resistant men, in contrast to our previous study, in which an equivalent dose of intranasal insulin significantly suppressed EGP in lean, insulin‐sensitive men. Insulin resistance is probably associated with impairment in centrally mediated insulin suppression of EGP.